Subtype
Hepatocellular Carcinoma
CI-CAN-00002853HCC · LIHCExplore in graph →
693 active trials13 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002853HCC · LIHCExplore in graph →
Clinical trials
3,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (357)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02794337 | TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer(TACE-SBRT) | unknown | Phase 2 / Phase 3 | 67 | Tata Memorial HospitalOTHER_GOV | 1 | Apr 27, 2022 | clinicaltrials |
| NCT01761266 | A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma | completed | Phase 3 | 954 | Eisai LimitedINDUSTRY | 21 | Apr 5, 2022 |
| clinicaltrials |
| NCT03605706 | A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment. | unknown | Phase 3 | 396 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 10, 2022 | clinicaltrials |
| NCT02192671 | HR Versus RFA for HCC in Patients With PHT(HR-HCC/PHT) | unknown | Phase 3 | 120 | Guangxi Medical UniversityOTHER | 1 | Jan 18, 2022 | clinicaltrials |
| NCT03988998 | Radiofrequency Ablation Plus Radiotherapy for Small Hepatocellular Carcinoma | unknown | Phase 3 | 100 | Guangxi Medical UniversityOTHER | 0 | Jan 18, 2022 | clinicaltrials |
| NCT03338647 | SBRT or TACE for Advanced HCC | unknown | Phase 3 | 180 | University of AarhusOTHER | 1 | Dec 2, 2021 | clinicaltrials |
| NCT01387932 | HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer(HiQuality) | terminated | Phase 3 | 235 | Merit Medical Systems, Inc.INDUSTRY | 5 | Nov 30, 2021 | clinicaltrials |
| NCT04595864 | Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation | recruiting | Phase 3 | 40 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Nov 5, 2021 | clinicaltrials |
| NCT05056337 | Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC | unknown | Phase 3 | 220 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT01655693 | Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma(ReLive) | completed | Phase 3 | 397 | Valerio TherapeuticsINDUSTRY | 11 | Jun 2, 2021 | clinicaltrials |
| NCT04909866 | The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study | unknown | Phase 2 / Phase 3 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT01908426 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib(CELESTIAL) | completed | Phase 3 | 707 | ExelixisINDUSTRY | 19 | May 6, 2021 | clinicaltrials |
| NCT01887717 | Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein(YES-P) | terminated | Phase 3 | 36 | Boston Scientific CorporationINDUSTRY | 6 | Apr 21, 2021 | clinicaltrials |
| NCT01755767 | Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy(METIV-HCC) | completed | Phase 3 | 383 | Daiichi SankyoINDUSTRY | 16 | Apr 6, 2021 | clinicaltrials |
| NCT04167293 | Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01)(ISBRT01) | unknown | Phase 2 / Phase 3 | 116 | Mian XIOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT04803019 | Transarterial Embolization Alone Versus Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma(RAD-18-TAcE) | unknown | Phase 3 | 154 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Mar 19, 2021 | clinicaltrials |
| NCT04665609 | Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC | unknown | Phase 3 | 80 | Chinese PLA General HospitalOTHER | 1 | Mar 4, 2021 | clinicaltrials |
| NCT02460991 | A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma(SOLACE) | terminated | Phase 3 | 2 | Boston Scientific CorporationINDUSTRY | 1 | Feb 12, 2021 | clinicaltrials |
| NCT04229355 | DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma | unknown | Phase 3 | 90 | Guangxi Medical UniversityOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT03794440 | A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma. | unknown | Phase 2 / Phase 3 | 595 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jan 22, 2021 | clinicaltrials |
| NCT04687163 | Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial | unknown | Phase 3 | 400 | Sun Yat-sen UniversityOTHER | 1 | Jan 13, 2021 | clinicaltrials |
| NCT04667351 | HAIC of Oxaliplatin, and 2400 mg/m² 5-fu vs HAIC of Oxaliplatin, and 1200 mg/m² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority Trial | unknown | Phase 3 | 400 | Sun Yat-sen UniversityOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT03898921 | RFA vs. SBRT for Small HCC | unknown | Phase 3 | 270 | Sun Yat-sen UniversityOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT04546802 | HepATocellular Cancer Hcv Therapy Study(HATCHeT) | withdrawn | Phase 3 | 0 | Bayside HealthOTHER_GOV | 0 | Sep 14, 2020 | clinicaltrials |
| NCT01774344 | Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma(RESORCE) | completed | Phase 3 | 573 | BayerINDUSTRY | 21 | Aug 20, 2020 | clinicaltrials |
| NCT03642561 | Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE | unknown | Phase 2 / Phase 3 | 300 | Fudan UniversityOTHER | 1 | Jul 28, 2020 | clinicaltrials |
| NCT02169765 | HR Versus RFA for Early Stage HCC(ARTC-HCC) | unknown | Phase 3 | 120 | Guangxi Medical UniversityOTHER | 1 | Jul 22, 2020 | clinicaltrials |
| NCT03974074 | Albumin for Hepatocellular Carcinoma | unknown | Phase 3 | 200 | Guangxi Medical UniversityOTHER | 1 | Jul 22, 2020 | clinicaltrials |
| NCT02971345 | Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus | unknown | Phase 3 | 253 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT03780049 | HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B | unknown | Phase 3 | 304 | Sun Yat-sen UniversityOTHER | 1 | May 21, 2020 | clinicaltrials |
| NCT04392700 | A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection | unknown | Phase 3 | 706 | Sun Yat-sen UniversityOTHER | 1 | May 19, 2020 | clinicaltrials |
| NCT03592706 | Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy | unknown | Phase 2 / Phase 3 | 60 | Ivy Life Sciences, Co., LtdINDUSTRY | 1 | Apr 16, 2020 | clinicaltrials |
| NCT03116984 | A Study of Comparison of TACE Combination With and Without EBRT for Advanced HCC(TACE-EBRT) | unknown | Phase 3 | 300 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT03990974 | Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC After Liver Resection(HCC) | suspended | Phase 3 | 458 | Sun Yat-sen UniversityOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT04143191 | Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC(SOURCE) | unknown | Phase 3 | 158 | Sun Yat-sen UniversityOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT04237740 | Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver Transplantation(RRHCCLT) | unknown | Phase 3 | 40 | RenJi HospitalOTHER | 0 | Mar 24, 2020 | clinicaltrials |
| NCT04319484 | Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus(LLTHVV) | unknown | Phase 2 / Phase 3 | 108 | RenJi HospitalOTHER | 0 | Mar 24, 2020 | clinicaltrials |
| NCT01833299 | Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma | completed | Phase 3 | 120 | Sun Yat-sen UniversityOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT02867280 | Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection | terminated | Phase 3 | 154 | Sun Yat-sen UniversityOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT02436902 | Adjuvant Therapies for Patients With HCC and MVI(A-TACE/S-HCC) | unknown | Phase 3 | 240 | Guangxi Medical UniversityOTHER | 1 | Jan 10, 2020 | clinicaltrials |
| NCT04044651 | Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection | withdrawn | Phase 2 / Phase 3 | 0 | Shi MingOTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT04202523 | Combined Radiotherapy and Radiofrequency Ablation for Hepatocellular Carcinoma | unknown | Phase 3 | 50 | Guangxi Medical UniversityOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02774187 | Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC | completed | Phase 3 | 247 | Sun Yat-sen UniversityOTHER | 1 | Dec 5, 2019 | clinicaltrials |
| NCT00908752 | Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC(BRISK TA) | completed | Phase 3 | 734 | Bristol-Myers SquibbINDUSTRY | 13 | Dec 2, 2019 | clinicaltrials |
| NCT03851913 | The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Beyond Milan Criteria BCLC Stage A/B Hepatocellular Carcinoma Who Underwent Hepatectomy | unknown | Phase 3 | 344 | Sun Yat-sen UniversityOTHER | 1 | Nov 29, 2019 | clinicaltrials |
| NCT04168944 | Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma | unknown | Phase 2 / Phase 3 | 108 | RenJi HospitalOTHER | 0 | Nov 19, 2019 | clinicaltrials |
| NCT04006275 | Comparing SonoVue With Sonazoid Using CEUS-LIRADS in HCC | unknown | Phase 3 | 100 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 19, 2019 | clinicaltrials |
| NCT01287585 | Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy(ADI-PEG 20) | completed | Phase 3 | 636 | Polaris GroupINDUSTRY | 6 | Sep 6, 2019 | clinicaltrials |
| NCT04025437 | Neoadjuvant Radiotherapy for HCC Involving Type I PVTT | unknown | Phase 2 / Phase 3 | 214 | Guangxi Medical UniversityOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT03905967 | TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC(TACE) | unknown | Phase 3 | 336 | Sun Yat-sen UniversityOTHER | 1 | Aug 20, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Apr 27, 2022source: clinicaltrials